Literature DB >> 28537937

Dexmedetomidine: the new all-in-one drug in paediatric anaesthesia?

Cedric E Sottas1, Brian J Anderson.   

Abstract

PURPOSE OF REVIEW: Dexmedetomidine is a drug with sedative, anxiolytic, sympatholytic and analgesic properties, which is finding widespread practice in paediatric anaesthesia and related practices. The present review summarizes its pharmacology and current experience with the drug. RECENT
FINDINGS: Dexmedetomidine is proving useful in many diverse areas in paediatric anaesthesia where its sedative properties are useful for premedication, fibreoptic intubation and radiologic procedures. Its use as an adjunct for balanced anaesthesia where it can decrease the use of other drugs, reduce emergence delirium, postoperative shivering and vomiting. Muted apoptotic neuroprotective effects may realize benefits in neonates. Cardiac conduction delay, an adverse effect, may prove beneficial for arrhythmias after congenital cardiac surgery.
SUMMARY: Most of the paediatric published studies concerning dexmedetomidine are observational in nature, with limited control groups or comparators. Adverse effects (e.g. bradycardia) still require greater scrutiny in the paediatric population and particularly with respect to different age groups. Dexmedetomidine currently has a firm position in the armamentarium of anaesthesia pharmacology. It is not the new all-in-one drug, but it is shaping up as a valuable adjunct for diverse indications within paediatric anaesthesia. VIDEO ABSTRACT: http://links.lww.com/COAN/A44.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28537937     DOI: 10.1097/ACO.0000000000000488

Source DB:  PubMed          Journal:  Curr Opin Anaesthesiol        ISSN: 0952-7907            Impact factor:   2.706


  19 in total

1.  Prognostic significance of α- and β2-adrenoceptor gene expression in breast cancer patients.

Authors:  Ezequiel Mariano Rivero; Leandro Marcelo Martinez; Carlos David Bruque; Lucia Gargiulo; Ariana Bruzzone; Isabel Alicia Lüthy
Journal:  Br J Clin Pharmacol       Date:  2019-07-31       Impact factor: 4.335

2.  Dexmedetomidine improved respiratory dynamics and arterial blood gas indices in patients with esophageal cancer after induction of anesthesia.

Authors:  Jian Chen; Baoli Chen; Ailuan Chen
Journal:  Am J Transl Res       Date:  2022-08-15       Impact factor: 3.940

Review 3.  Pharmacokinetic Pharmacodynamic Modelling Contributions to Improve Paediatric Anaesthesia Practice.

Authors:  James D Morse; Luis Ignacio Cortinez; Brian J Anderson
Journal:  J Clin Med       Date:  2022-05-26       Impact factor: 4.964

Review 4.  Postoperative Nausea and Vomiting in Pediatric Patients.

Authors:  Anthony L Kovac
Journal:  Paediatr Drugs       Date:  2020-10-27       Impact factor: 3.022

Review 5.  Mechanisms of Dexmedetomidine in Neuropathic Pain.

Authors:  Yang Zhao; Jianshuai He; Ning Yu; Changxin Jia; Shilei Wang
Journal:  Front Neurosci       Date:  2020-05-05       Impact factor: 4.677

6.  Dexmedetomidine alleviates LPS‑induced acute lung injury via regulation of the p38/HO‑1 pathway.

Authors:  Yingying Sun; Yin Xia; Xinghui Liu; Junxia Liu; Weitian He; Hongwu Ye; Xianren Yuan
Journal:  Mol Med Rep       Date:  2020-07-10       Impact factor: 2.952

7.  Effect of Single-Dose Dexmedetomidine on Intraoperative Hemodynamics and Postoperative Recovery during Pediatric Adenotonsillectomy.

Authors:  Kiran Sharma; Mritunjay Kumar; Ranju Gandhi
Journal:  Anesth Essays Res       Date:  2019 Jan-Mar

8.  Dexmedetomidine-based monitored conscious sedation combined local anesthesia for levator resection in a 10-year-old child with Marcus Gunn jaw-winking synkinesis: A case report.

Authors:  Ye Tu; Feng Gao
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

9.  Ketamine Enhances Intranasal Dexmedetomidine-Induced Sedation in Children: A Randomized, Double-Blind Trial.

Authors:  Bin Qian; Wenting Zheng; Jiawei Shi; Zihan Chen; Yanhua Guo; Yusheng Yao
Journal:  Drug Des Devel Ther       Date:  2020-08-26       Impact factor: 4.162

10.  Dexmedetomidine suppresses the progression of esophageal cancer via miR-143-3p/epidermal growth factor receptor pathway substrate 8 axis.

Authors:  Peisen Zhang; Hefan He; Yuyan Bai; Weifeng Liu; Lirong Huang
Journal:  Anticancer Drugs       Date:  2020-08       Impact factor: 2.389

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.